Characterization and measurement of prostate-specific antigen using monoclonal antibodies.

Monoclonal and polyclonal antibodies were produced using a pure preparation of prostate-specific antigen (PSA) as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). By SDS-PAGE, the apparent molecular weight of PSA was about 33 kD. Eighty-four monoclonal antibodies were produced, 77 of which bind PSA with an affinity higher than 10(9) M-1. Use of these monoclonal antibodies to study the immunological characteristics of PSA revealed the presence of 4 epitopes. Injection of PSA into goats resulted in a production of polyclonal antibodies with high affinity. These polyclonal antibodies were purified by affinity chromatography and adsorbed on plastic tubes. By an immunometric assay, we have also demonstrated that polyclonal antibodies bind PSA at a fifth epitope that is different from those of monoclonal antibodies. Using an iodinated monoclonal antibody and polyclonal antibodies adsorbed on plastic tubes, a sensitive immunoradiometric assay could be developed, and a further increase in sensitivity could be achieved by using a mixture of 2 monoclonal antibodies. The serum PSA levels in 2,250 patients measured with this immunoradiometric assay were identical to the values determined by Tandem-R, although the present assay reached a minimum detectable value of 0.05 ng/ml compared with 0.2 ng/ml by Tandem-R.

Isolation of IFAPa-400 cDNAs: evidence for a transient cytostructural gene activity common to the precursor cells of the myogenic and the neurogenic cell lineages.

Differentiation of neural and muscle cells is characterized by a switch in the expression of the type of intermediate filament protein subunit. In these lineages, vimentin is transiently expressed in the initial stages of development and is gradually replaced by a tissue specific protein. We have identified a giant developmentally regulated antigen (IFAPa-400) which colocalizes with vimentin in the precursor cells of the neurogenic and myogenic lineages of the chick embryo [Chabot and Vincent (1990) Dev. Brain Res. 54, 195-204; Cossette and Vincent (1991) J. Cell Sci. 98, 251-260]. Based on the expression of this protein during neurogenesis and myogenesis, we hypothesize that IFAPa-400 and vimentin define a special intermediate filament network, common to the non-differentiated cells derived from the neuroectoderm and those of the myogenic tissues. We report here the isolation and sequence of partial cDNAs encoding more than 400 amino acids of the carboxy-terminus of this protein. RNA blot analysis and in situ hybridization indicate that IFAPa-400 represents a bona fide developmentally regulated gene product. These results further confirm that IFAPa-400 mRNA transcripts are limited to the early precursor cells of both neurogenic and myogenic lineages.

The neural tube/notochord complex is necessary for vertebral but not limb and body wall striated muscle differentiation.

The aim of this work was to investigate the role played by the axial organs, neural tube and notochord, on the differentiation of muscle cells from the somites in the avian embryo. Two of us have previously shown that neuralectomy and notochordectomy is followed by necrosis of the somites and consecutive absence of vertebrae and of most muscle cells derived from the myotomes while the limbs develop normally with muscles. Here we have focused our attention on muscle cell differentiation by using the 13F4 mAb that recognizes a cytoplasmic antigen specific of all types of muscle cells. We show that differentiation of muscle cells of myotomes can occur in the absence of notochord and neural tube provided that the somites from which they are derived have been in contact with the axial organs for a defined period of time, about 10 hours for the first somites formed at the cervical level, a duration that progressively reduces caudalward (i.e. for thoracic and lumbar somites). Either one or the other of the two axial organs, the neural tube or the notochord can prevent somitic cell death and fulfill the requirements for myotomal muscle cell differentiation. Separation of the neural tube/notochord complex from the somites by a surgical slit on one side of the embryo gave the same results as extirpation of these organs and provided a perfect control on the non-operated side. A striking finding was that limb and body wall muscles, although derived from the somites, differentiated in the absence of the axial organs. However, limb muscles that develop after excision of the neural tube started to degenerate from E10 onward due to lack of innervation. In vitro explantation of somites from different axial levels confirmed and defined precisely the chronology of muscle cell commitment in the myotomes as revealed by the in vivo experiments.

Myoblast migration specifically inhibited in the chick embryo by grafted CSAT hybridoma cells secreting an anti-integrin antibody.

We report a teratological method in which mouse hybridoma cells are grafted into a chick host. CSAT (Cell Substratum ATtachment) hybridoma was used. It produces an antibody directed against the avian integrin complex. The grafts were performed during the second and third days of incubation either at the level of the somites or in the coelom of the chick embryo. The anomalies were revealed by means of a monoclonal antibody that recognizes myogenic cells as soon as they become committed in the myotome. When embryos were grafted at the level of the somites, body wall muscles failed to develop on the side of the graft only. After coelomic grafting, total agenesis of abdominal muscles was induced. The anomalies were specific since the engraftment of three control hybridoma clones induced no change in muscle formation. These control hybridomas produce antibodies directed against the same molecular complex but not against the same epitope as CSAT. The injection of hybridoma cells in an embryo appears as a method of general interest to determine the long-term consequences of perturbing a specific developmental process.

Heart tumors specifically induced in young avian embryos by the v-myc oncogene.

To determine if expression of the v-myc oncogene had any effect during ontogeny, we injected avian myelocytomatosis virus strain MC29 into avian embryos at various stages of development. The injection of MC29 at embryonic day 2 (E2) or 3 (E3) caused, about 10 days later, rhabdomyosarcomas of the heart and, in some cases, skin muscle hypertrophy. When the injection was performed at E4 or E5, the number of heart tumors declined, whereas the number of skin muscle tumors increased significantly. The p110gag-myc protein was found in all tumors analyzed. When the virus was injected intravenously into E10 embryos, no tumors appeared during embryonic life, in striking contrast to the results obtained from injections at earlier stages. The monoclonal antibody 13F4, which is specific for the myogenic lineage, bound strongly to tumoral heart tissue, whereas it bound weakly to normal cardiac cells. Comparison of the peaks of tumor incidence in relationship to the timing of injection suggests that the v-myc product could interfere in vivo with an early step of the muscle lineage differentiation program. In addition, we show that the p58c-myc protein, which is supposed to play an important role in the control of cell proliferation, is only faintly detected in the heart of normal E3 embryos, in contrast to limb and tail buds, which readily express detectable levels of p58c-myc.

A monoclonal antibody specific for avian early myogenic cells and differentiated muscle.

A monoclonal antibody raised in mouse in response to homogenates of Remark ganglia and dorsal mesentery of chicken embryos was found to exhibit a unique reactivity towards myogenic cells, heart, striated muscles, and smooth muscles in chicken and quail. Indirect immunofluorescence assays were performed at different stages of chicken and quail embryonic development and, after hatching, on tissue sections and cultured cells. They revealed that the cytoplasmic marker recognized by 13F4 is expressed in early embryonic heart, in somitic myotome (from stage 14 onward), in the skeletal muscles in limbs and trunk, in all muscles in the head and the branchial arches, in the smooth muscles of the digestive tract and blood vessels. In myofibrils of striated muscles, the antigen is localized in the Z lines. The antigenicity of the molecule recognized by 13F4 is not associated with a glycolipid or a glycoprotein. It is of peptidic nature and its molecular weight is 54 kDa. We stress the value of this cell-type-specific marker in studies on ontogenesis and differentiation of all muscular structures, namely, of myocardium and striated muscles, which express 13F4 antigenicity from an early developmental stage.

Heterogeneity in migrating neural crest cells revealed by a monoclonal antibody.

A monoclonal antibody, GlN1, obtained by immunization with extracts of the 14 d embryonic quail nodose ganglion, is described. GlN1 recognizes an antigenic determinant present in virtually all the satellite cells of the peripheral ganglia, all Schwann cells of the peripheral nerves, and in subpopulations of sensory and autonomic neurons of embryonic and adult quails and chickens. The molecular weight of the antigen(s) revealed by GlN1 in embryonic day 12 quail dorsal root ganglion (DRG) cultures is around 80 kDa. In the neural crest, GlN1 determinant is found as soon as the crest cells leave the neural primordium. Only a proportion (25%) of the migrating neural crest cells carry the antigen. This demonstrates that the neural crest is composed of a heterogeneous population of cells from its early migratory stages. Being selectively distributed on neural crest cells and its derivatives, the GlN1 determinant may be considered as a "differentiation antigen" that will be useful in further studies on cell-line segregation during the ontogeny of the PNS.